Science & Innovation
Life and health are invaluable. That is why Abbott concentrates on applying
breakthrough science to develop effective treatments across its broad base of
businesses – devices, pharmaceuticals and nutritionals – to solve unmet medical
needs for people around the world. We define science as any innovation that
will lead to improved health care options – from new approaches to drug
discovery to easy-to-read packaging that helps patient compliance.
Abbott scientists are advancing thinking in areas such as diabetes,
immunology, nutritionals, oncology and vascular disease. The pace of our work
in the discovery and development of new technologies and treatments is enhanced
by our global network of more than 7,000 scientists in Brussels, Canada,
Germany, Japan, Mexico, and the United States (Austin, Texas, Lake County,
Illinois, Columbus, Ohio, Santa Clara, California and Worcester,
Massachusetts).
Science: Our Foundation
The quality of our science is reflected in our diagnostic and therapeutic
advances – and in the strides we have made in the science of discovery. We
invent novel diagnostic and treatment options in a number of disciplines,
including therapies that target specific causes of immunological diseases; new
methods of minimally invasive blood glucose testing; and important work in the
field of drug-eluting and bioabsorbable stents for vascular procedures; and
many others.
From goals as diverse as developing proprietary advanced technologies that
can shorten the time necessary to identify disease targets and produce the
drugs that act against these targets, to inventing innovative and helpful
packaging that gives parents more convenient baby formula options or
pharmacists easier labels to read, our scientists are continuously looking for
the best methods to improve lives.
From Breakthroughs to Improvements
Even in its earliest days, Abbott recognized the rich therapeutic potential
of biologics and predicted that approaches to medicine would include both
biologics and small molecules. In addition to breakthroughs using each of those
approaches, we have made improvements to certain delivery systems: for example,
using Meltrex technology, Kaletra is now in a tablet form. Abbott is
continually investing in novel approaches to the discovery of new medicines
such as conducting the first ever natural history study to advance the
scientific understanding about the role of vulnerable plaque in heart attacks;
creating imaging tools that reveal how medicine reacts in the body; and
creating compounds for research purposes that lead to an increased
understanding of Alzheimer's disease and the pain process.